Unmet Needs With Car T Therapy in Multiple Myeloma: Nina Shah, MD

Video

The hematologist and oncologist from the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center discussed unmet needs with CAR T-cell therapy in multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Nina Shah, MD, hematologist/oncologist and associate professor of medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, about unmet needs with CAR T-cell therapy in multiple myeloma.

Shah discussed how CAR T-cell therapy has not quite managed to cure patients with multiple myeloma and no plateau has been seen on the survival curves, although the therapies have been a welcome addition to the treatment landscape. Innovative ways to prolong the efficacy of CAR T-cell therapy are being investigated, Shah said.

Unique culturing techniques, such as those utilized with the investigational bb21217 product, are being evaluated. Additionally, engineering techniques aimed at increasing the T-stem cell–like memory phenotype are being studied with the P-BCMA-101 product. Finally, allogenic CAR T-cell therapies, such as those being developed by Allogene Therapeutics, have the potential to increase accessibility to CAR T-cell therapy in multiple myeloma, Shah explained.

Ultimately, refining the culturing, engineering, and manufacturing process of CAR T-cell therapy may improve the success of this therapeutic modality and provide prolonged responses to patients with multiple myeloma, Shah concluded.

Recent Videos
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
© 2025 MJH Life Sciences

All rights reserved.